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Over-expression of the adhesion molecule CD44 and its splice variants, especially CD44v6, is associated with poor prognosis
and metastasis. We aimed at regulating the expression of CD44 in the highly metastatic human colon cancer cell line HM7
and thereby affecting its metastatic ability. HM7 cells show constitutive expression of CD44 standard and variants isoforms,
which were signiﬁcantly down-regulated by treatment with butyrate. Butyrate signiﬁcantly inhibited transcription of the CD44
gene and abolished epidermal growth factor-mediated up-regulation of the reporter gene luciferase subcloned upstream to
the CD44 promoter (–1.1 kb) and transfected to HM7 cells. Nuclear proteins from butyrate-treated cells bound to an
epidermal growth factor receptor element motif present in the CD44 promoter. Epidermal growth factor receptor element-
site directed mutations eliminated the inducibility of the luciferase reporter gene and did not allowed binding of nuclear
proteins harvested from butyrate-treated cells. Butyrate induced CD44 gene repression by speciﬁcally interacting with an
epidermal growth factor receptor element nuclear transcriptional factor. This interaction affects CD44 transcriptional activity
vis-a `-vis in vivo metastatic ability of HM7 cells. These results provide additional insight into the anticarcinogenic properties of
butyrate.
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Adhesion molecules expressed on metastatic or disseminated cells
are indispensable for the cell’s transmigration through the endothe-
lium, locomotion in the blood-lymph circulation, and localization
in the target organ (Lester and MacCarthy, 1992). Homotypic and
heterotypic, cell-to-cell and cell-to-matrix interactions are involved
in each of these steps (Herrera-Gayol and Jothy, 1999). CD44 is
one of the few proteins able to fulﬁl this dual role. CD44 comprises
a family of many glycoprotein isoforms (Rudzki and Jothy, 1997).
The CD44 variant isoforms differ from the standard form, CD44s,
in their proximal extracellular region. There, 10 exons, designated
v1 to v10, can be inserted by alternative splicing (Screaton et al,
1992). CD44 is a widely distributed cell-adhesion molecule that
has been implicated in the metastasis of lymphomas and epithelial
tumours, such as colorectal cancer. In human cancer, CD44 splice
variants are frequently expressed in advanced stages of tumorigen-
esis. Structural analysis of the CD44 upstream regulatory region in
human neuroblastoma cells revealed that there is a cis-regulatory
element that contributes to downregulation of the CD44 gene. This
epidermal growth factor (EGF) regulatory element (ERE) sequence
of CD44 (Shtivelman and Bishop, 1991), unlike other cis-acting
elements that contain the Sp1 site, comprises a speciﬁcally oriented
22-bp sequence, necessary to enable EGF-induced CD44 gene tran-
scription through a speciﬁc interaction between the ERE motif and
an unknown transcription factor. Point mutations within this
sequence alter CD44 transcription (Zhang et al, 1997).
Butyrate is a short-chain fatty acid formed in the gastrointest-
inal tract of mammals as a result of anaerobic bacterial
fermentation of undigested dietary components, and is avidly
absorbed by the colonic epithelium. Treatment of mammalian
cells in vitro with millimolar concentrations of butyrate has
pleiotropic effects on cellular physiology (Hassing et al, 1997;
Schwartz et al, 1998; Barshishat et al, 2000). Butyrate exerts
several effects on nuclear proteins that could modify gene expres-
sion (Nakano et al, 1997; Archer et al, 1998). The aim of the
present study was to assess whether CD44 can be regulated in
high metastatic colon cancer cell line expressing high levels of
this polymorphic glycoprotein and whether this regulation could
affect metastasis.
MATERIALS AND METHODS
All media and supplements were purchased from Biological Indus-
tries (Beit Haemek, Israel) and all biochemicals from Sigma
Chemical Co. (St. Louis, MO, USA) unless otherwise speciﬁed.
Cell line, culture conditions and treatments
HM7 is a cell variant of LS174T, a well-differentiated human colo-
nic adenocarcinoma previously shown to be highly metastatic in
vitro (Schwartz et al, 1992) and in vivo (Bresalier et al, 1995). Cells
were treated with butyrate (2 mM) for 9 days to induce terminal
differentiation as described (Schwartz et al, 1995a). Cells were trea-
ted with 100 mM of the stable phosphorthioate CD44v6-antisense
oligonucleotide (5'-CTTCCGTTGTACTACTAGGA-3') or missense
control oligonucleotide (5'-TTTTTTAAAAGGGGCCCCCT-3').
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nology (Rehovot, Israel).
Western blot analysis
One hundred micrograms cell protein lysates were separated in
10% SDS–PAGE and transferred to a nylon-transfer membrane
(Amersham, Buckinghamshire, UK). A positive control protein
supplied by the company was included in each analysis. The
CD44 protein was reacted with mouse monoclonal anti-human
CD44v6 antibody (VFF-18 clone, BMS125, Bender MedSystems,
Austria) and visualised by enhanced chemiluminescence kit (ECL,
Amersham).
Immunocytochemistry
Cells were grown in 8-well chamber slides, ﬁxed and immunos-
tained with a 1:140 dilution of the anti-CD44v6 monoclonal
antibody (V6-B3 clone, Zymed, San Francisco, CA, USA) in block-
ing buffer. Detection was performed with Vectastain Elit kit Vector
Laboratories (Burlingame, CA, USA). Counterstaining was
performed with haematoxylin (Schwartz et al, 1995b).
Nuclear run-off
HM7 cells were lysed and their nuclei isolated. ATP, CTP, GTP
(2 mM each), UTP (0.04 mM ) and 4 mlo f[ g-
32P]UTP (from
3000 mCi) (NENTM Life Science Products, Boston, MA, USA)
were added to the nuclear suspension (100 ml) and incubated for
30 min. The samples were extracted with phenol/chloroform and
precipitated. Five micrograms of the following cDNA probes were
slot-blotted onto a nylon transfer membrane (Amersham) and
hybridised with the precipitated samples at equal counts per min
per ml in hybridisation buffer at 458C for 48 h: CD44v6 (5'-TGG-
CATGAGGGATATCGCCAAACACCCAGA-3') CD44s: (5'-TCTG-
GGTGTTTGGCGATATCCCTCATGCCA-3') and b-actin: (5'-GC-
ATGGGTCAGAAGGATTCC-3'). The ﬁlters were washed, and the
radioactive signals on the autoradiograms were measured using a
Fujix Phosphor-Imager apparatus and a BAS-1000 Bio-Imaging
Analyzer (Fuji Co., Japan), or exposed to X-ray ﬁlm.
CD44 reverse transcription-polymerase chain reaction
(RT-PCR)
cDNA was synthesised from 1 to 5 mg of total RNA from control,
antisense- or butyrate-treated cells, using an RT–PCR kit (A1250
Promega, Madison, WI, USA). RT–PCR was performed with the
prevously reported primers and under similar conditions (Gotley
et al, 1996): forward primers from exon 10 (10F):5 '-TCCAGG-
CAACTCCTAGTAGTACAA-3', or exon 3 (3F):5 '-'TCCCAGTA-
TGACACATATTGC-3', and reverse primers from exon 17 (17R):
5'-CCAAGATGATCAGCCATTCTGG-3' or exon 11 (11R):5 '-
GATGGCTGGTATGAGCTGAGGCTG-3'.
Sequence analysis
Sequence analysis of the CD44 variants’ (RT–PCR products’)
cDNA was performed with an automatic thermocyclin sequencing
3700 DNA analyzer ABI prism (Perkin Elmer, Forester City, CA,
USA).
Fluorescence-activated cell sorter (FACS) analysis
Cells were incubated with saturating amounts of anti-CD44v6 or
anti-CD44s antibodies (H-CAM, clone F10-44-2, Serotec, Raleigh,
NC, USA) and then exposed to FITC (F (ab') fragment goat
anti-mouse IgG (H+L)) (Jackson Immuno-Research Laboratories,
Inc, West Grove, PA, USA) antibody and analysed by FACS
(FACSort, Becton Dickinson, San Jose, CA, USA).
Plasmid constructs, DNA transfection and luciferase assay
A fragment of the 5'-ﬂanking region of the human gene encoding
CD44 was ampliﬁed using the PromoterFinder Kit (CLONTECH,
Palo Alto, CA, USA). Primers were designed according to the
published human CD44 sequence promoter (Shtivelman and
Bishop, 1991). A CD44-speciﬁc primer and a nested primer were
used in the primary and secondary PCR’s, to amplify an 1100-bp
fragment from human genomic DNA, spanning part of the promo-
ter sequence and the ﬂanking 100 bp of the 5'-sequence of the
CD44 gene. The PCR fragment was subcloned into pSP72 (Prome-
ga) and automatically sequenced as described. The nested PCR
showed that the promoter sequence is similar to that published
previously (Shtivelman and Bishop, 1991) and includes the ERE
motif between –604 and –583, as described (Shtivelman and
Bishop, 1991; Zhang et al, 1997). The resultant 1100 bp fragment
was subcloned upstream of the luciferase reporter plasmid pGL3-
Basic which contains the luciferase gene to generate
pCD44(71000/+100)-luc. This construct was used to generate
point mutations of the CD44 promoter as described in the next
paragraph.
Site-directed mutagenesis
Speciﬁc nucleotides in the 1100 bp CD44 promoter were mutated
or deleted using the QuickChange Mutagenesis kit (Stratagene, La
Jolla, CA, USA). Brieﬂy, a pair of primers each containing two-
base-mutated oligonucleotides (from T to C (5'-CCCTCTC-
CCCAGCTCCCCTCCC-3') or from C to A (5'-CCCTCTATC-
CAGCTCCTATCCC-3')) was used to mutate the ERE-binding
site (7604/7583). The underlined nucleotides were introduced
into the mutant constructs, using the QuickChange Mutagenesis
kit. The plasmids resulting from the two substitutions were isolated
and the mutations conﬁrmed by digestion and by DNA sequen-
cing.
Transfection studies
HM7 cells were transfected with plasmid DNA (0.5 mg containing
the CD44 promoter construct or one of the mutants) and 1.5 ml
of FuGENE-6 transfection reagent (Roche Molecular Biochemicals,
Indianapolis, IN, USA) for 3 h. The transfected cells were treated
for 48 h with EGF (10 nM), butyrate (2 mM) or combinations
(incubation time shown to exert signiﬁcant effects), harvested by
centrifugation and washed with 16PBS, pH 7.4. Cell pellets were
lysed with 150 mlo f1 6Cell Culture Lysis Reagent (Promega).
Following 2 min centrifugation, luciferase activity and protein
content of the extracts were measured. For luciferase activity,
10 ml of the extracts were used to measure the integrated light units
over 10 s, using the luciferase assay system (Promega), as recom-
mended by the manufacturers.
Gel shift mobility assay
Nuclear proteins were extracted from 5610
6–10
7 control or buty-
rate-treated cells as previously described (Andrews and Faller,
1991). Synthetic oligonucleotides of the putative ERE sequence
(Zhang et al, 1997) and sequences from the mutated ERE oligonu-
cleotides (5'-CCCTCTCCCCAGCTCCCCTCCC-3')O R( 5 '-
CCCTCTATCCAGCTCCTATCCC-3') were annealed and 5'-end-
labelled with g-
32P-ATP by T4 kinase (BioLab New England,
Beverly, MA, USA). Each probe (2610
4 c.p.m.) was applied at a
1:1 ratio of premix gel shift reaction in the presence of 10 mgo f
nuclear extract on ice for 1 h. Poly(dI-dC) (0.2–2 mg) or 10–
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extracts on ice for 20 min before being reacted with the labelled
ERE probe. These unlabelled sequences (Poly(dI-dC) and ERE)
served as competition controls. DNA-protein complexes were
resolved on a native 4% nondenaturing polyacrylamide gel subse-
quently dried and autoradiographed (Carey, 1991).
Liver colonisation
The ability of control, butyrate-, antisense- and missense-treated
cells to colonise the liver of athymic mice (Balb/c) was tested as
previously described (Bresalier et al, 1995). The Animal Welfare
Committee of the Faculty of Agricultural, Food and Environmental
Quality Sciences, Hebrew University of Jerusalem supervised the
research protocols and animal care.
Statistical analysis
Results were expressed as mean+s.e.m. Statistical signiﬁcance was
calculated by Student’s t-test.
RESULTS
Butyrate regulates CD44 protein expression
HM7 control cells (Figure 1A), markedly expressed the CD44v6
variant on their surface membrane. Butyrate signiﬁcantly downre-
gulated CD44v6 expression in HM7 cells after 9 days of treatment
(Figure 1B). To demonstrate speciﬁcity of the antibody we incu-
bated the sections with both antibody and control peptide. The
control protein almost completely abrogated the capability of the
antibody to bind cellular antigens. Western immunoblotting with
monoclonal antibody to the v6 splice variant revealed expression
of various CD44v6 protein isoforms within the range of 97–
220 kDa in control cells, similarly to the lanes obtained with the
control peptide. Butyrate treatment induced signiﬁcant downregu-
lation of all CD44v6 isoforms, consistent with the immunostaining
results (Figure 1C).
Butyrate regulates CD44 gene expression
Nuclear run-off analyses showed that transcription of both the
constant and variant species of CD44 was reduced after butyrate
treatment (Figure 2A). RT–PCR analysis allowed detection of
alternative splice variants using speciﬁc primers to detect CD44
mRNA containing exon 10 (v6) or primers to the borders of the
CD44 constant region, in order to detect transcription of the
constant region (CD44s) and simultaneously of the larger splice
variants of CD44, including several exons of the variant region:
(i) RT–PCR assay using the 10F/17R set of primers resulted in a
single, evident PCR product of *840 bp (Figure 2B). Sequence
analysis demonstrated that this band includes all variable exon
regions from 10 to 16 and the exon 17 border and (ii) ampliﬁca-
tion with the set of primers 3F/11R resulted in a single product,
demonstrated by sequence analysis to include exons 3, 4, 5a, 10
and the border of exon 11 to give a PCR product of *480 bp
(Figure 2C). Transcription of the constant CD44 isoform was
obtained using the 3F/17R primers for both cell lines. In addition,
a number of additional CD44 variants of various sizes were
detected with this primer set (Figure 2D). The smallest detectable
band was at 492 bp and included exons 3, 4, 5a and 16 (non-vari-
able exons), and the border of exon 17. The second-most notable
product was at *880 bp, and its sequence analysis revealed the
inclusion of exons 3, 4, 5a, 14, 15, 16, and the border of exon
17. Butyrate treatment signiﬁcantly affected the expression of all
CD44 transcripts (Figure 2B–D), suggesting that the short-chain
fatty acid regulates the CD44 gene at the transcriptional level.
Butyrate regulates CD44 promoter activity
A sequence containing a signiﬁcant portion of the CD44 promoter
was generated and linked to pGL3-B which contains the luciferase
reporter gene to give the plasmid pCD44(71000/+100)-luc. Addi-
tion of EGF (10 nM) to pCD44(71000/+100)-luc-transfected HM7
cells for 48 h, led to a 5.5-fold increase in luciferase activity,
compared to cells treated transfected with control plasmid,
pGL3-B (Figure 3). Butyrate (2 mM) abrogated luciferase activity
induced by EGF in pCD44(71000/+100)-luc-transfected HM7
cells. Butyrate by its own did not affected luciferase activity in
the above-mentioned transfected HM7 cells. To investigate whether
the ERE region present in the promoter mediates the induction;
substitution-mutated constructs were designed to this speciﬁc
region in the CD44 promoter. A T–C mutation at sites 7592/
7587 reduced EGF-induced luciferase transduction by 75%, and
a C–A mutation at sites 7593/7586 reduced EGF-induced luci-
ferase transduction by 85% (Figure 3), indicating that this ERE
site is critical for EGF-induced CD44 gene regulation, and for
the down-regulatory effect exerted by butyrate.
Detection of ERE binding to CD44 promoter
To conﬁrm the involvement of ERE in the response to butyrate,
electrophoretic mobility shift assays were performed using a
labelled 22-bp ERE sequence or site-mutated EREs and nuclear
extracts from control or butyrate-treated HM7 cells. Pre-incubation
of the labelled ERE with 100 ng unlabelled ERE or 1 mg (dI-dC)
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Figure 1 Expression of CD44v6 in HM7 cells. Immunocytochemistry:
(A) (Magniﬁcation (M): 640): HM7 cells strongly expressed CD44v6.
(B) (M: 640): In Butyrate-treated HM7 cells a reduced expression of
CD44v6 is observed. (C) (M: 640): Addition of the control protein con-
comitantly with the anti-CD44v6 antibody almost completely abrogated
the binding capacity of the antibody to HM7 cellular antigens. Western im-
munoblotting: (D): The CD44v6 antibody distinguished CD44v6 isoforms
within the range of 97–220 kDa either in the control protein as well as in
HM7 cells incubated under control conditions (CT) or in butyrate-treated
HM7 cells (NB). Representative results from four similar experiments.
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probe compared to 10 ng of ERE or 0.2 mg of (dI-dC) (Figure
4A,B). Neither the T–C nor the C-to-A mutated ERE fragments
at the indicated sites (see Materials and Methods), bound nuclear
extracts of the colon cancer cell line studied (Figure 4C illustrate
only the -C–A mutation, the T–C mutation yielded identical
results). Butyrate treatment markedly enhanced the formation of
protein-DNA complex on the gel, compared to control untreated
cells (Figure 4D,E). However, the effect of 100 mg nuclear proteins
was most noticeable. These results suggest that the ERE motif
located in the CD44 promoter sequence speciﬁcally binds nuclear
proteins from butyrate-treated cells that may be lacking or exist
at very low concentrations in control HM7 cells.
Effect of antisense treatment on CD44v6 expression
We examined the expression of CD44v6 in HM7 cells after treatment
with antisense oligonucleotide speciﬁc to exon 10 (v6) or missense
oligonucleotides by RT–PCR. At lower concentrations of total
RNA (3 and 4 mg) the expression of CD44v6 mRNA was not detect-
able in the antisense-treated cells (Figure 5). Only at 5 mg of total
RNA did expression become evident. In contrast, in control and
missense-treated HM7 cells, there was high expression of the variant
at all concentrations of total RNA added to the RT–PCR assay.
CD44s and CD44v6 protein expression assessed by FACS analy-
sis (Table 1) show down-regulation of CD44v6 protein expression
in HM7 cells treated with CD44v6-antisense compared to control
or missense-treated cells. In contrast, the expression of CD44s
was barely affected by CD44v6-antisense treatment in HM7 cells
relative to control or missense-treated cells. FACS analyses demon-
strated that butyrate signiﬁcantly (P50.001) down-regulates the
expressions of both of CD44s and CD44v6, conﬁrming our
previous Western and imunocytochemical analyses.
Effect of CD44 gene regulation on in vivo liver colonisation
ability of HM7 cells
As expected, control HM7 cells injected into the spleen of athymic
Balb/c mice were able to actively colonise the mouse livers, and
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Figure 2 CD44 gene transcription. Nuclear run-off analysis of CD44s and CD44v6 in control HM7 cells (CT) or treated with butyrate (NB) (A). HM7
cells transcribed the CD44v6 splice variant. The same results were found for the constant isoform (CD44s). Butyrate inhibited the transcription of both
isoforms. RNA loading was veriﬁed with b-actin probe. Effect of butyrate treatment on the expression of different splice variants was measured by
RT–PCR analysis using primers 10F/17R (B), 3F/11R (C) and 3F/17R (D). Similar results were obtained in 3–5 different experiments.
EGF EGF+Butyrate Butyrate
(–1100/+100),
–593/–586
(–1100/+100),
–592/–587)
(–1100/+100)
pGL3-B
0                   2                  4                   6                   8
CD 44 promoter activity (fold-stimulation)
Figure 3 Inducibility of the CD44 promoter. The CD44 promoter linked
to a luciferase reporter gene pCD44(71000/+100)-luc was transfected
into HM7 cells. The transfected cells were treated for 48 h with EGF
(10 nM), butyrate (2 mM) or combinations. Addition of EGF to the trans-
fectants (71100/+100) led to a 5.7-fold increase in luciferase activity, com-
pared to cells transfected with pGL3-B. The construct (71000/
+100)7592/7587 is the promoter linked to luciferase containing a T–
C mutation at sites 7592/7587 and (71100/+100)7593/7586 is the
promoter linked to luciferase containing a C–A mutation at sites 7593/
7586. Results are mean+s.e.m. of three independent experiments.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1314–1320resulted in signiﬁcant tumour burden (mean 256+98 nodules per
liver, range 49–500, n=15, Table 2) and the appearance of epithe-
loid tumours (Figure 6A see arrows, and Figure 7A). In HM7 cells
treated with butyrate (2 mM) the liver colonisation ability was
abolished (Figure 6B). Histology of mouse liver sections showed
normal hepatocytes with no inﬁltration of cells of epithelial origin
(Figure 7B). HM7 cells treated with CD44v6-antisense oligonucleo-
tides resulted in a signiﬁcantly smaller number of micrometastatic
foci (26+20 nodules per liver, P50.003). Control non-injected
mice exhibited normal livers with no metastatic foci (Figures 6D
and 7B).
DISCUSSION
Functional studies have demonstrated an important role of the
expression of CD44 variants and metastasis (Gunther et al, 1991;
Herrera-Gayol and Jothy, 1999). These observations led us to ques-
tion whether and how regulation of the expression of CD44
isoforms, including the commonly expressed CD44v6 variant,
would affect the metastatic ability of HM7 colon cancer cells. We
showed that HM7 cells express high levels of CD44v6, as evidenced
by immunocytochemical, Western blot and FACS analyses. RT–
PCR analyses with primers to several regions of the CD44 gene
were used to characterise the repertoire of CD44 variants expressed
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
10        100 10       100 0.2          1 CT         NB CT         NB
ERE
Poly
(dI-dC)
ERE
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Figure 4 Butyrate-induced protein-ERE complex formation in a gel shift assay. DNA-protein complex formation was measured using
32P-labelled 22 bp
ERE probe and nuclear extracts of HM7 cells. Competition in protein-DNA formation: 10 and 100 ng unlabelled ERE (A), 0.2 and 1 mg poly(dI-dC) (B)
were incubated with HM7 nuclear extracts before adding labelled ERE probe. Binding speciﬁcity determined with 10 and 100 ng
32P-labelled C–A replaced
ERE probe at the sites indicated by underline (5'-CCCTCTATCCAGCTCCTATCCC-3') and incubated with nuclear extracts of HM7 cells (C, ERE mu-
tated). Nuclear extracts from control (CT) or butyrate-treated (NB) cells were incubated with the labelled ERE probe. The binding was dependent on the
concentration of the nuclear protein extracts (D;1 0mg, E; 100 mg). Representative results from three similar experiments.
123       3          4         5 3          4           5
M CT
µg RNA
Cd44v6-antisense
µg RNA
861 bp —
Figure 5 Effect of butyrate and CD44v6-antisense oligonucleotide treat-
ments. CD44v6 isoform including exon 10 was obtained by RT–PCR,
using 10F/17R primers in HM7 cells treated with antisense oligonucleotide.
Antisense treatment caused a reduction in the mRNA expression of the
CD44v6 splice variant. CT: 3, 4 and 5 mg total RNA from control HM7 cells
(CT) or CD44v6-antisense treated cells were used in the RT–PCR assays.
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doses of CD44 protein and its variants by treating the cells with
butyrate. We selected this agent because in a recent study
(Barshishat et al, 2000), we demonstrated that butyrate treatment
is able to convert the passive essential promoter of E-cadherin to
an active form, thereby affecting gene expression. Butyrate inhibits
histone deacetylase leading to histone hyperacetylation (Hennig et
al, 1995), which can alter chromatin structure and affect accessibil-
ity of transcription factors to their recognition sequences, recruit
other factors, and control transcription by activation or depression.
In butyrate-treated HM7 cells, CD44v6 protein expression was
signiﬁcantly downregulated. Nuclear run-off and RT–PCR analyses
demonstrated that butyrate treatment affect transcription of the
entire CD44 gene, not just of speciﬁc CD44 variants. RT–PCR
analysis conﬁrmed the nuclear run-off ﬁndings and showed that
any expressed splice variant was drastically downregulated follow-
ing butyrate treatment.
To establish the mechanism by which butyrate exerts gene tran-
scription repression we created an 1100-bp fragment from human
genomic DNA. This sequence spanned part of the promoter
sequence and the ﬂanking 100 bp of the 5'-sequence of the
CD44 gene (71000/+100), linked to pGL3-B which contains the
luciferase gene to generate pCD44(71000/+100)-luc. We identiﬁed
a 22-bp consensus regulatory element to EGF (ERE) within this
sequence, between –604 to –583, supporting previous ﬁndings
(Shtivelman and Bishop, 1991; Zhang et al, 1997). Then, two-
base-targeted mutations of this sequence at ERE site (7604 and
–583) were obtained. The intact (71000/+100) promoter
responded maximally to EGF treatment. Butyrate completely abro-
gated this EGF-mediated CD44 promoter activity. Butyrate by itself
did not affected promoter activity. Mutations targeted to the ERE
sequence completely eliminated the luciferase inducibility of the
CD44 promoter exerted by EGF, and the respective inhibitory
action exerted by butyrate. We then demonstrated that butyrate
induces binding of nuclear proteins speciﬁcally to ERE since
point-mutated ERE constructs did not bind nuclear proteins
following butyrate treatment. The speciﬁc nuclear proteins induced
by butyrate to bind to ERE remain to be identiﬁed, but since the
motif is related to EGF, it is plausible to assume that they are
related to this growth factor.
We next asked whether butyrate treatment affects CD44-
mediated biological activity, in an in vivo experimental setting.
The in vivo liver colonisation assay following intrasplenic injection
of metastatic HM7 cells into nude mice demonstrate that these
cells were able to invade the liver, proliferate and create metastatic
tumours. HM7 cells treated with CD44v6-antisense oligonucleo-
tides exhibited a signiﬁcantly lower capacity to create metastatic
nodules in the mouse livers. Remarkably, butyrate-treated HM7
cells completely lost their ability to colonise the livers of nude
mice. Inoculation of HM7 cells treated with butyrate (1 mM, data
not shown) into nude mice induced a more moderate reduction in
liver nodule formation (256+98 in control to 90+5 in butyrate
treated, 65% reduction). Inoculation of HM7 cells treated with
butyrate (0.1 mM, data not shown) into nude mice induced a more
borderline reduction in liver nodule formation (256+98 in control
to 190+25 in butyrate treated, 25% reduction). Regarding the time
window, at 2 mM concentration 9 days also gave optimal results,
while 5 and 7 days of treatment were less effective (not shown).
These ﬁndings suggest that CD44v6 is an essential variant protein
for metastatic cell growth in the host organ (Kaya et al, 1997).
Reducing the expression of the CD44v6 variant by antisense treat-
ment resulted in signiﬁcant inhibition of metastatic nodule
development. However, pan-deregulation of several other CD44
variants appears to be more effective. In line with these ﬁndings,
Reeder et al (1998) reported that HT29 cells transfected with anti-
sense vectors to CD44 exon 10 and inoculated into nude mice
result in mice completely free of metastasis for 16 weeks, as
compared to a 30% metastasis rate in the control HT29 parental
and vector inoculated mice for the same period. The relatively
low incidence of metastasis obtained following inoculation of
parental HT29 cells may be explained by the fact that this cell line
is not highly metastatic as are HM7 cells, which are able to
produce 100% metastasis incidence after only 6 weeks. Harada et
al (2001) ﬁndings further support our study: they show that mice
intrasplenically injected with LS174T cell transfectants with anti-
sense CD44s vectors were completely free of metastasis as
compared to mice injected with the parental LS174T cells. Trans-
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HM7   Control HM7 CD44v6-antisense
HM7 Butyrate-treated Normal livers not-injected mice
Figure 6 Liver colonisation model. Livers from athymic nude mice 6
weeks after splenic injection of HM7 control cells (A), butyrate-treated
cells (B) CD44v6-antisense treated cells (C) compared to non-injected
animals (D). Results are representative of three independent identical
experiments.
HM7 Butyrate-treated HM7 cells AB
Normal liver not injected C
Figure 7 Sections from mouse after liver colonisation assay. H&E stain-
ing of liver sections obtained from mice after splenic injection with HM7
cells (A), with butyrate-treated HM7 cells (B) or normal liver sections from
non-injected mice (C). Liver tissue and texture was signiﬁcantly affected
following splenic injection with the highly metastatic HM7 cells (A).
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CD44 variants, an effect that in our study we achieve following
treatment with butyrate. Since CD44 variants serve as low-afﬁnity
receptors for growth factors (Ponta et al, 1998, Sherman et al,
1998), reducing CD44 variants expression may result in the preven-
tion of growth factor presentation and in the concomitant
inhibition of metastatic tumour development.
Since butyrate controls the expression of additional genes, we
cannot exclude the possibility that they might also play a role in
the observed dramatic inhibition of metastasis.
We believe that butyrate control the expression of additional
genes involved in metastasis. We have shown previously that buty-
rate upregulates E-cadherin transcription and expression
(Barshishat et al, 2000), a molecule known to act as tumour
suppressor gene in metastasis. In addition, a recent publication
by Pelizzaro et al (2002), show that butyrate induced a dose-depen-
dent down-regulation of VEGF165 protein, a potent angiogenic
factor and vis-a `-vis up-regulates the hypoxia-inducible factor
(HIF)-1a. Our reported effects on CD44 and the effects reported
by our group previously (Barshishat et al, 2000) and by Pelizarro
et al (2002) may induce altogether the signiﬁcant effects induced
by butyrate observed in vivo on metastatic formation. Nevertheless,
the pan-deregulatory effect exerted by butyrate in the entire CD44
gene seems to play a key role in the complete abolishment of meta-
static ability exhibited by HM7 cells. CD44 variants bind to a wide
variety of ECM constituents and growth factors which have been
shown previously to play different roles in tumour invasion, moti-
lity and metastasis (Katagiri et al, 1999), and downregulation of
their expression may be pivotal for the metastatic cascade to take
place.
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